Literature DB >> 22487771

Differences in the locomotor-activating effects of indirect serotonin agonists in habituated and non-habituated rats.

Adam L Halberstadt1, Mahálah R Buell, Diana L Price, Mark A Geyer.   

Abstract

The indirect serotonin (5-HT) agonist 3,4-methylenedioxymethamphetamine (MDMA) produces a distinct behavioral profile in rats consisting of locomotor hyperactivity, thigmotaxis, and decreased exploration. The indirect 5-HT agonist α-ethyltryptamine (AET) produces a similar behavioral profile. Using the Behavioral Pattern Monitor (BPM), the present investigation examined whether the effects of MDMA and AET are dependent on the novelty of the testing environment. These experiments were conducted in Sprague-Dawley rats housed on a reversed light cycle and tested during the dark phase of the light/dark cycle. We found that racemic MDMA (RS-MDMA; 3 mg/kg, SC) increased locomotor activity in rats tested in novel BPM chambers, but had no effect on locomotor activity in rats habituated to the BPM chambers immediately prior to testing. Likewise, AET (5 mg/kg, SC) increased locomotor activity in non-habituated animals but not in animals habituated to the test chambers. These results were unexpected because previous reports indicate that MDMA has robust locomotor-activating effects in habituated animals. To further examine the influence of habituation on MDMA-induced locomotor activity, we conducted parametric studies with S-(+)-MDMA (the more active enantiomer) in habituated and non-habituated rats housed on a standard or reversed light cycle. Light cycle was included as a variable due to reported differences in sensitivity to serotonergic ligands during the dark and light phases. In confirmation of our initial studies, rats tested during the dark phase and habituated to the BPM did not show an S-(+)-MDMA (3 mg/kg, SC)-induced increase in locomotor activity, whereas non-habituated rats did. By contrast, in rats tested during the light phase, S-(+)-MDMA increased locomotor activity in both non-habituated and habituated rats, although the response in habituated animals was attenuated. The finding that habituation and light cycle interact to influence MDMA- and AET-induced hyperactivity demonstrates that there are previously unrecognized complexities associated with the behavioral effects of these drugs.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22487771      PMCID: PMC3354037          DOI: 10.1016/j.pbb.2012.03.023

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  70 in total

1.  Differentiation of presumed serotonergic dorsal raphe neurons in relation to behavior and wake-sleep states.

Authors:  K Sakai; S Crochet
Journal:  Neuroscience       Date:  2001       Impact factor: 3.590

2.  Diurnal differences in rat's motor response to amphetamine.

Authors:  O Gaytan; A Swann; N Dafny
Journal:  Eur J Pharmacol       Date:  1998-03-19       Impact factor: 4.432

Review 3.  Differences between the mechanism of action of MDMA, MBDB, and the classic hallucinogens. Identification of a new therapeutic class: entactogens.

Authors:  D E Nichols
Journal:  J Psychoactive Drugs       Date:  1986 Oct-Dec

4.  Psychological and physiological effects of MDMA ("Ecstasy") after pretreatment with the 5-HT(2) antagonist ketanserin in healthy humans.

Authors:  M E Liechti; M R Saur; A Gamma; D Hell; F X Vollenweider
Journal:  Neuropsychopharmacology       Date:  2000-10       Impact factor: 7.853

5.  Psychopathological, neuroendocrine and autonomic effects of 3,4-methylenedioxyethylamphetamine (MDE), psilocybin and d-methamphetamine in healthy volunteers. Results of an experimental double-blind placebo-controlled study.

Authors:  E Gouzoulis-Mayfrank; B Thelen; E Habermeyer; H J Kunert; K A Kovar; H Lindenblatt; L Hermle; M Spitzer; H Sass
Journal:  Psychopharmacology (Berl)       Date:  1999-02       Impact factor: 4.530

6.  Effects of DOM and DMT in a proposed animal model of hallucinogenic activity.

Authors:  L M Adams; M A Geyer
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  1985       Impact factor: 5.067

7.  Behavioral characterization of alpha-ethyltryptamine, a tryptamine derivative with MDMA-like properties in rats.

Authors:  K M Krebs; M A Geyer
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

8.  Effects of dopamine D1- or D2-like receptor antagonists on the hypermotive and discriminative stimulus effects of (+)-MDMA.

Authors:  Marcy J Bubar; Kami M Pack; Paul S Frankel; Kathryn A Cunningham
Journal:  Psychopharmacology (Berl)       Date:  2004-04-03       Impact factor: 4.530

9.  (+)-N-methyl-1-(1,3-benzodioxol-5-yl)-2-butanamine as a discriminative stimulus in studies of 3,4-methylenedioxy-methamphetamine-like behavioral activity.

Authors:  R Oberlender; D E Nichols
Journal:  J Pharmacol Exp Ther       Date:  1990-12       Impact factor: 4.030

10.  The safety and efficacy of {+/-}3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study.

Authors:  Michael C Mithoefer; Mark T Wagner; Ann T Mithoefer; Lisa Jerome; Rick Doblin
Journal:  J Psychopharmacol       Date:  2010-07-19       Impact factor: 4.153

View more
  1 in total

1.  Powerful cocaine-like actions of 3,4-methylenedioxypyrovalerone (MDPV), a principal constituent of psychoactive 'bath salts' products.

Authors:  Michael H Baumann; John S Partilla; Kurt R Lehner; Eric B Thorndike; Alexander F Hoffman; Marion Holy; Richard B Rothman; Steven R Goldberg; Carl R Lupica; Harald H Sitte; Simon D Brandt; Srihari R Tella; Nicholas V Cozzi; Charles W Schindler
Journal:  Neuropsychopharmacology       Date:  2012-10-17       Impact factor: 7.853

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.